Shenzhen Salubris Pharmaceutical Co., Ltd. is a public comprehensive pharmaceutical group, ranking Top 10 in China’s pharmaceutical industry in terms of market value and among the 20 Most Competitive Listed Pharmaceutical Companies in China. Its business covers 38 countries and regions in the world including China, the United States, Germany, France and Japan.
Focusing on the cardiovascular and cerebrovascular, diabetes and complications, anti-tumor and orthopedics. Focusing on the three main businesses of high-end pharmaceutical chemicals, innovative biologics and medical devices. Maintaining the leading position in cardiovascular and cerebrovascular medicine.
The research institute of the company consists of three parts: chemical drug development, biologics development and medical devices. The research team consists of nearly 1,000 members, including returning doctors, senior experts and senior researchers, working on more than 100 research projects.
For latest news and events.
The company deals with investors in a fair, just and objective manner, delivers the company information comprehensively and accurately, demonstrates its values, enhances the information exchange and positive interaction between investors and the company, establishes sincere and harmonious investor relationship, promote the realization of strategic target of the company and realize the mutual development of the company and investors.
Since the establishment, Salubris has been sticking to the value of “better life from sincerity” and persistent in fulfilling social responsibilities.
We respect the value of employees, provide equal opportunities, professional training and study platform for employees, help employees to improve work performance and personal ability, and promote the mutual development of employees and the company.